-
-
公开(公告)号：CA2527866A1
公开(公告)日：2005-01-13
申请号：CA2527866
申请日：2004-07-01
Applicant: CELLTECH R&D LTD
Inventor： HUMPHREYS DAVID PAUL , HEYWOOD SAM PHILIP
IPC: C07K16/00 , A61K39/395
Abstract: The present invention relates to a new class of antibody fragments including antibody Fab and Fab' fragments in which the heavy chain is not covalently bonded to the light chain and two or more effector molecules are attached to the fragment, of which at least one of said molecules is attached to a cysteine in the heavy or light chain constant region.
-
公开(公告)号：CA2527020A1
公开(公告)日：2005-01-13
申请号：CA2527020
申请日：2004-07-01
Applicant: CELLTECH R&D LTD
Inventor： HEYWOOD SAM PHILIP , HUMPHREYS DAVID PAUL
IPC: C07K16/00 , A61K39/395
Abstract: The present invention provides antibody Fab fragments in which the heavy chain constant region terminates at the interchain cysteine of CH1. Also provided are antibody Fab fragments in which the heavy chain constant region terminates at the interchain cysteine of CH1 to which one or more effector molecules are attached.
-
公开(公告)号：NO20044742L
公开(公告)日：2004-12-22
申请号：NO20044742
申请日：2004-11-02
Applicant: CELLTECH R&D LTD
Abstract: There is disclosed antibody molecules containing at least one CDR derived from a mouse monoclonal antibody having specificity for human CD22. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a modified CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases mediated by cells expressing CD22.
-
公开(公告)号：NO20044742A
公开(公告)日：2004-12-22
申请号：NO20044742
申请日：2004-11-02
Applicant: CELLTECH R&D LTD
CPC classification number: C07K16/464 , A61K2039/505 , A61K2039/507 , C07K16/2803 , C07K16/2851 , C07K16/3061 , C07K2317/20 , C07K2317/24 , C07K2317/40 , C07K2317/41 , C07K2317/52 , C07K2317/56 , C07K2317/565 , C07K2317/567 , C07K2317/76 , C07K2317/92
-
Patent Agency Ranking
公开(公告)号：GB0425537D0
公开(公告)日：2004-12-22
申请号：GB0425537
申请日：2004-11-19
Applicant: CELLTECH R&D LTD
Abstract: The present invention relates to the manufacture of recombinant antibodies of therapeutic quality. In particular, the invention relates to methods for increasig the yield of cuntional antibody from large scale fermentations whereby a cultured host cell sample is subjected to a freeze-thaw treatment step.
-
-
公开(公告)号：CA2526880A1
公开(公告)日：2004-11-04
申请号：CA2526880
申请日：2004-04-08
Applicant: CELLTECH R&D LTD
Inventor： MEISSNER JOHANNES WILHELM GEOR , WATSON ROBERT JOHN , OWEN DAVID ALAN
IPC: C07D211/58 , A61K31/452 , A61P37/02 , A61P37/08 , C07D409/12
Abstract: Compounds of formula (1) wherein,m,n,R1,R2,Ra,ALK3, E and Y are as defined i n the claims, being potent and selective inhibitors of chemokine binding to th e CXCR3 receptor, are accordingly of use in the treatment and/or prevention of conditions involving inappropriate T-cell trafficking, including inflammator y, autoimmune and immurforegulatory disorders such as rheumatoid arthritis.
-
公开(公告)号：IL161384D0
公开(公告)日：2004-09-27
申请号：IL16138402
申请日：2002-10-16
Applicant: CELLTECH R&D LTD
IPC: A61K31/4365 , A61K31/437 , A61K31/444 , A61K31/4545 , A61K31/496 , A61K31/5377 , A61P1/04 , A61P1/16 , A61P3/10 , A61P5/14 , A61P7/02 , A61P7/06 , A61P9/00 , A61P9/04 , A61P9/10 , A61P11/00 , A61P11/06 , A61P13/12 , A61P17/00 , A61P17/06 , A61P19/02 , A61P19/08 , A61P19/10 , A61P21/04 , A61P25/00 , A61P25/16 , A61P25/28 , A61P29/00 , A61P31/04 , A61P31/12 , A61P31/14 , A61P31/18 , A61P31/20 , A61P35/00 , A61P35/02 , A61P35/04 , A61P37/00 , A61P37/02 , A61P37/06 , A61P37/08 , A61P43/00 , C07D471/04 , C07D495/04 , C07D
Abstract: Compounds of formulae (1a) and (1b) are described: in which the dashed line represents an optional bond; A is a -N- atom or a -N(R b )-, -C(R b )- or -C(R b )(R C )- group; R a , R b and R c is each independently a hydrogen atom or an optionally substituted C 1-6 alkyl group; X is an -O- or -S- atom or -NH- group or substituted N atom; each Y is independently a N atom or CH group or substituted C atom; n is zero or the integer 1; Alk 1 is an optionally substituted aliphatic or heteroaliphatic chain L 1 is a covalent bond or a linker atom or group; Cy 1 is a hydrogen atom or an optionally substituted cycloaliphatic, polycycloaliphatic, heterocycloaliphatic, polyheterocycloaliphatic, aromatic or heteroaromatic group; Ar is an optionally substituted aromatic or heteroaromatic group; and the salts, solvates, hydrates and N-oxides thereof; The compounds are potent inhibitors of p38 kinase and are use in the prophylaxis or treatment of p38 kinase mediated diseases or disorders, such as rheumatoid arthritis
-
公开(公告)号：IL160849D0
公开(公告)日：2004-08-31
申请号：IL16084902
申请日：2002-10-10
Applicant: CELLTECH R&D LTD
IPC: C12N15/09 , A61K39/395 , A61K47/48 , A61P17/00 , A61P17/06 , A61P19/02 , A61P29/00 , A61P35/00 , A61P35/04 , A61P37/00 , C07K16/28 , C12N1/15 , C12N1/19 , C12N1/21 , C12N5/10 , C12N15/13 , C12P21/02 , C12P21/08 , C12N
Abstract: There are disclosed antibody molecules containing at least on CDR derived from a mouse monoclonal antibody having specificity for human KDR. There is also disclosed a CDR grafted antibody wherein at least one of the CDRs is a hybrid CDR. Further disclosed are DNA sequences encoding the chains of the antibody molecules, vectors, transformed host cells and uses of the antibody molecules in the treatment of diseases in which VEGF and/or KDR are implicated.
-
-
-
-
-
-
-
-
-
Search Results
485
records
(took 0.026 seconds)
